Search results for "cancer vaccination"

showing 3 items of 3 documents

The European regulatory environment of rna-based vaccines

2016

A variety of different mRNA-based drugs are currently in development. This became possible, since major breakthroughs in RNA research during the last decades allowed impressive improvements of translation, stability and delivery of mRNA. This article focuses on antigen-encoding RNA-based vaccines that are either directed against tumors or pathogens. mRNA-encoded vaccines are developed both for preventive or therapeutic purposes. Most mRNA-based vaccines are directly administered to patients. Alternatively, primary autologous cells from cancer patients are modified ex vivo by the use of mRNA and then are adoptively transferred to patients. In the EU no regulatory guidelines presently exist t…

0301 basic medicineAutologous cellMessenger RNAVaccinesAnticancer vaccinationGenetically modified medicinal productsbusiness.industryGenetic enhancementmRNARNAGenetic therapy03 medical and health sciences030104 developmental biology0302 clinical medicineAntigenPreventive and therapeutic approachesInfectious disease (medical specialty)030220 oncology & carcinogenesisAdvanced therapy medicinal products (ATMP)ImmunologyMedicineVaccination against infectious diseasebusinessRegulatory framework in the EUEx vivo
researchProduct

Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots

2021

Contains fulltext : 244693.pdf (Publisher’s version ) (Open Access) Synthetic cancer vaccines may boost anticancer immune responses by co-delivering tumor antigens and adjuvants to dendritic cells (DCs). The accessibility of cancer vaccines to DCs and thereby the delivery efficiency of antigenic material greatly depends on the vaccine platform that is used. Three-dimensional scaffolds have been developed to deliver antigens and adjuvants locally in an immunostimulatory environment to DCs to enable sustained availability. However, current systems have little control over the release profiles of the cargo that is incorporated and are often characterized by an initial high-burst release. Here,…

Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]T-LymphocytesT cellBiomedical Engineering02 engineering and technologySDG 3 – Goede gezondheid en welzijnantigen-specific T cellsCancer VaccinesArticleBiomaterials03 medical and health sciencesbiomaterial-based scaffoldsImmune systemAntigenSDG 3 - Good Health and Well-beingAntigen specificControlled deliverymedicineLactic Aciddendritic cells030304 developmental biology0303 health sciencesChemistryBiomaterial021001 nanoscience & nanotechnologyCell biologymedicine.anatomical_structureDelivery efficiencynanoparticles0210 nano-technologycancer vaccinationNanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19]Polyglycolic Acid
researchProduct

Targeting the tumor mutanome for personalized vaccination therapy

2012

Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source for effective vaccines.

next generation sequencingSomatic cellbusiness.industryImmunologyBioinformaticscancer immunogenicityDNA sequencingEpitopeVaccinationOncologyImmunizationIn vivoImmunogenic tumornon-synonymous mutationsCancer researchindividualized therapyImmunology and AllergyMedicinetumor mutationsB16f10 melanomacancer vaccinationbusinessAuthor's ViewOncoImmunology
researchProduct